Table 1.
Demographics and smoking characteristics
| Variable | Baclofen (n = 21) | Placebo (n = 22) | Group comparisons | |
|---|---|---|---|---|
|
| ||||
| t or x 2 | p value | |||
| Sex, male | 13 (62) | 14 (64) | 0.01 | 0.91 |
| Age | 38.9 ± 12 | 40.2 ± 12 | −0.47 | 0.64 |
| IQ | 97.4 ± 12.1 | 103.8 ± 12.4 | −1.64 | 0.11 |
| Race | ||||
| African American | 12 (55) | 14 (64) | 0.19 | 0.66 |
| Caucasian | 7 (33) | 6 (27) | 0.19 | 0.67 |
| Asian | 2 (10) | 2 (9) | < 0.01 | 0.96 |
| Ethnicity | ||||
| Hispanic | 1 (0.1) | 3 (0.1) | < 0.01 | 1.0 |
| Education | 13.3 ± 1.8 | 14 ± 1.8 | −1.06 | 0.29 |
| Alcohol use | ||||
| Endorsed use | 12 (50) | 13 (59.1) | 0.02 | 0.87 |
| Drinks per drinking day, T1a | 2.7 ± 2.10 | 3.1 ± 2.4 | 0.46 | 0.65 |
| Cannabis use | ||||
| Endorsed use | 7 (31.8) | 8 (36.4) | < 0.01 | 1.0 |
| Days of cannabis use, T1a | 5 ± 2.6 | 4.5 ± 2.4 | 0.23 | 0.82 |
| Smoking characteristics | ||||
| FTND | 4.9 ± 1.5 | 4.9 ± 1.5 | 0.19 | 0.85 |
| Pack years | 16.6 ± 13.8 | 15.6 ± 12.6 | 0.23 | 0.82 |
| CPD | ||||
| T1 | 14.4 ± 5.7 | 13.9 ± 4.8 | 0.35 | 0.73 |
| T2 | 12.9 ± 7.5 | 9.5 ± 4.7 | 1.72 | 0.09 |
Values are presented as number (%) or mean ± standard deviation.
T1, before treatment; T2, on medication and after 3 weeks of treatment; FTND, Fagerström Test for Nicotine Dependence; CPD, cigarettes per day.
a
In participants who used this substance in the last 30 days, measured by the Timeline Follow Back. There were no differences between groups in any demographics or smoking characteristics.